236 related articles for article (PubMed ID: 32171760)
1. Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF.
Cunningham JW; Ferreira JP; Deng H; Anker SD; Byra WM; Cleland JGF; Gheorghiade M; Lam CSP; La Police D; Mehra MR; Neaton JD; Spiro TE; van Veldhuisen DJ; Greenberg B; Zannad F
JACC Heart Fail; 2020 May; 8(5):359-368. PubMed ID: 32171760
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
Mehra MR; Vaduganathan M; Fu M; Ferreira JP; Anker SD; Cleland JGF; Lam CSP; van Veldhuisen DJ; Byra WM; Spiro TE; Deng H; Zannad F; Greenberg B
Eur Heart J; 2019 Nov; 40(44):3593-3602. PubMed ID: 31461239
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.
Zannad F; Greenberg B; Cleland JG; Gheorghiade M; van Veldhuisen DJ; Mehra MR; Anker SD; Byra WM; Fu M; Mills RM
Eur J Heart Fail; 2015 Jul; 17(7):735-42. PubMed ID: 25919061
[TBL] [Abstract][Full Text] [Related]
4. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Greenberg B; Neaton JD; Anker SD; Byra WM; Cleland JGF; Deng H; Fu M; La Police DA; Lam CSP; Mehra MR; Nessel CC; Spiro TE; van Veldhuisen DJ; Vanden Boom CM; Zannad F
JAMA Cardiol; 2019 Jun; 4(6):515-523. PubMed ID: 31017637
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Zannad F; Anker SD; Byra WM; Cleland JGF; Fu M; Gheorghiade M; Lam CSP; Mehra MR; Neaton JD; Nessel CC; Spiro TE; van Veldhuisen DJ; Greenberg B;
N Engl J Med; 2018 Oct; 379(14):1332-1342. PubMed ID: 30146935
[TBL] [Abstract][Full Text] [Related]
6. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.
Myhre PL; Vaduganathan M; Claggett BL; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Desai AS; Lewis EF; Rouleau J; Pitt B; Pfeffer MA; Solomon SD
JAMA Cardiol; 2018 Oct; 3(10):1000-1005. PubMed ID: 30140899
[TBL] [Abstract][Full Text] [Related]
7. High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial.
Monzo L; Girerd N; Ferreira JP; Lamiral Z; Anker SD; Cleland JGF; Kondo T; McMurray JJV; Lam CSP; Mehra MR; Veldhuisen DJV; Greenberg B; Zannad F
J Card Fail; 2024 Apr; 30(4):618-623. PubMed ID: 38122924
[TBL] [Abstract][Full Text] [Related]
8. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
Pieske B; Patel MJ; Westerhout CM; Anstrom KJ; Butler J; Ezekowitz J; Hernandez AF; Koglin J; Lam CSP; Ponikowski P; Roessig L; Voors AA; O'Connor CM; Armstrong PW;
Eur J Heart Fail; 2019 Dec; 21(12):1596-1604. PubMed ID: 31820546
[TBL] [Abstract][Full Text] [Related]
9. Impact of Geographic Region on the COMMANDER-HF Trial.
Ferreira JP; Cleland JGF; Lam CSP; van Veldhuisen DJ; Byra WM; La Police DA; Anker SD; Mehra MR; Leroy C; Eschwege V; Toussaint-Hacquard M; Rossignol P; Greenberg B; Zannad F
JACC Heart Fail; 2021 Mar; 9(3):201-211. PubMed ID: 33549557
[TBL] [Abstract][Full Text] [Related]
10. Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study.
Savarese G; Donal E; Hage C; Oger E; Persson H; Daubert JC; Linde C; Lund LH;
Int J Cardiol; 2017 Jan; 226():65-70. PubMed ID: 27788392
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
12. Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial.
Ferreira JP; Lam CSP; Anker SD; Mehra MR; van Veldhuisen DJ; Byra WM; La Police DA; Cleland JGF; Greenberg B; Zannad F
Eur J Heart Fail; 2021 Apr; 23(4):648-656. PubMed ID: 32959502
[TBL] [Abstract][Full Text] [Related]
13. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
Branch KR; Probstfield JL; Eikelboom JW; Bosch J; Maggioni AP; Cheng RK; Bhatt DL; Avezum A; Fox KAA; Connolly SJ; Shestakovska O; Yusuf S
Circulation; 2019 Aug; 140(7):529-537. PubMed ID: 31163978
[TBL] [Abstract][Full Text] [Related]
15. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
16. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
17. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
Ehteshami-Afshar S; Mooney L; Dewan P; Desai AS; Lang NN; Lefkowitz MP; Petrie MC; Rizkala AR; Rouleau JL; Solomon SD; Swedberg K; Shi VC; Zile MR; Packer M; McMurray JJV; Jhund PS; Hawkins NM
J Am Heart Assoc; 2021 Feb; 10(4):e019238. PubMed ID: 33522249
[TBL] [Abstract][Full Text] [Related]
19. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.
Docherty KF; Jhund PS; Claggett B; Ferreira JP; Bengtsson O; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; McMurray JJV;
JAMA Cardiol; 2021 Nov; 6(11):1298-1305. PubMed ID: 34319398
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF.
Sharma A; Caldeira D; Razaghizad A; Pinto FJ; van Veldhuisen DJ; Mehra MR; Lam CSP; Cleland J; Anker SD; Greenberg B; Ferreira JP; Zannad F
BMJ Open; 2023 Aug; 13(8):e068865. PubMed ID: 37567750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
